礼来的IL-17A单抗Taltz治疗非放射性轴向脊柱关节炎,III期临床试验大获成功

2019-04-23 不详 MedSci原创

礼来宣布其IL-17A单抗Taltz(ixekizumab)用于未接受过治疗的非放射性轴性脊柱关节炎(nr-axSpA)患者,在III期临床试验COAST-X中达到所有主要次要终点。根据该实验结果,该公司计划今年在nr-axSpA治疗上获得Taltz的监管批准。

礼来宣布其IL-17A单抗Taltz(ixekizumab)用于未接受过治疗的非放射性轴性脊柱关节炎(nr-axSpA)患者,在III期临床试验COAST-X中达到所有主要次要终点。根据该实验结果,该公司计划今年在nr-axSpA治疗上获得Taltz的监管批准。

Lilly总裁Christi Shaw评论道:"COAST-X试验结果让我们很受鼓舞,这一结果很可能让Taltz成为第一个在美国获批用于治疗nr-axSpA的IL-17A单抗。"

Taltz在16周和52周时通过显着改善nr-axSpA的体征和症状,从而达到了COAST-X的主要终点。Taltz还在两个时间点都达到了主要的次要目标,包括改善强直性脊柱炎疾病活动评分(ASDAS)和巴斯强直性脊柱炎疾病活动(BASDAI),以及达到低疾病活动患者比例(ASDAS <2.1)。

礼来公司表示,Taltz在COAST-X的安全性与先前报道的后期研究"一致",没有检测到新的安全问题。

Taltz于2016年在美国获得批准用于治疗中度至重度斑块状银屑病患者,于2018年获批了Taltz 的标签更新,用于治疗生殖器区域的牛皮癣。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (15)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2088740, encodeId=1d272088e40f9, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Nov 18 20:17:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916098, encodeId=2a111916098e8, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Dec 15 19:17:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662165, encodeId=117816621659e, content=<a href='/topic/show?id=27b4964139' target=_blank style='color:#2F92EE;'>#IL-17A单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9641, encryptionId=27b4964139, topicName=IL-17A单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b3425366251, createdName=ms7899726347904398, createdTime=Mon Aug 26 13:17:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931461, encodeId=c2b4193146153, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Feb 03 21:17:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652888, encodeId=a6011652888b6, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Dec 29 07:17:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674292, encodeId=21c016e42921d, content=<a href='/topic/show?id=a5261e119fc' target=_blank style='color:#2F92EE;'>#Taltz#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17119, encryptionId=a5261e119fc, topicName=Taltz)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9a26964526, createdName=hjwang88, createdTime=Sun Sep 08 21:17:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861312, encodeId=1f58186131243, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Oct 21 04:17:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265955, encodeId=d874126595582, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu Apr 25 11:17:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318698, encodeId=fb2c1318698de, content=<a href='/topic/show?id=6b4a845138d' target=_blank style='color:#2F92EE;'>#脊柱关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84513, encryptionId=6b4a845138d, topicName=脊柱关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2bcd469, createdName=fengting3, createdTime=Thu Apr 25 11:17:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374425, encodeId=014f13e4425b1, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9638, encryptionId=1727963861, topicName=IL-17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Thu Apr 25 11:17:00 CST 2019, time=2019-04-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2088740, encodeId=1d272088e40f9, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Nov 18 20:17:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916098, encodeId=2a111916098e8, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Dec 15 19:17:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662165, encodeId=117816621659e, content=<a href='/topic/show?id=27b4964139' target=_blank style='color:#2F92EE;'>#IL-17A单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9641, encryptionId=27b4964139, topicName=IL-17A单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b3425366251, createdName=ms7899726347904398, createdTime=Mon Aug 26 13:17:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931461, encodeId=c2b4193146153, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Feb 03 21:17:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652888, encodeId=a6011652888b6, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Dec 29 07:17:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674292, encodeId=21c016e42921d, content=<a href='/topic/show?id=a5261e119fc' target=_blank style='color:#2F92EE;'>#Taltz#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17119, encryptionId=a5261e119fc, topicName=Taltz)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9a26964526, createdName=hjwang88, createdTime=Sun Sep 08 21:17:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861312, encodeId=1f58186131243, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Oct 21 04:17:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265955, encodeId=d874126595582, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu Apr 25 11:17:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318698, encodeId=fb2c1318698de, content=<a href='/topic/show?id=6b4a845138d' target=_blank style='color:#2F92EE;'>#脊柱关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84513, encryptionId=6b4a845138d, topicName=脊柱关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2bcd469, createdName=fengting3, createdTime=Thu Apr 25 11:17:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374425, encodeId=014f13e4425b1, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9638, encryptionId=1727963861, topicName=IL-17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Thu Apr 25 11:17:00 CST 2019, time=2019-04-25, status=1, ipAttribution=)]
    2019-12-15 juliusluan78
  3. [GetPortalCommentsPageByObjectIdResponse(id=2088740, encodeId=1d272088e40f9, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Nov 18 20:17:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916098, encodeId=2a111916098e8, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Dec 15 19:17:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662165, encodeId=117816621659e, content=<a href='/topic/show?id=27b4964139' target=_blank style='color:#2F92EE;'>#IL-17A单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9641, encryptionId=27b4964139, topicName=IL-17A单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b3425366251, createdName=ms7899726347904398, createdTime=Mon Aug 26 13:17:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931461, encodeId=c2b4193146153, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Feb 03 21:17:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652888, encodeId=a6011652888b6, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Dec 29 07:17:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674292, encodeId=21c016e42921d, content=<a href='/topic/show?id=a5261e119fc' target=_blank style='color:#2F92EE;'>#Taltz#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17119, encryptionId=a5261e119fc, topicName=Taltz)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9a26964526, createdName=hjwang88, createdTime=Sun Sep 08 21:17:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861312, encodeId=1f58186131243, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Oct 21 04:17:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265955, encodeId=d874126595582, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu Apr 25 11:17:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318698, encodeId=fb2c1318698de, content=<a href='/topic/show?id=6b4a845138d' target=_blank style='color:#2F92EE;'>#脊柱关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84513, encryptionId=6b4a845138d, topicName=脊柱关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2bcd469, createdName=fengting3, createdTime=Thu Apr 25 11:17:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374425, encodeId=014f13e4425b1, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9638, encryptionId=1727963861, topicName=IL-17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Thu Apr 25 11:17:00 CST 2019, time=2019-04-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2088740, encodeId=1d272088e40f9, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Nov 18 20:17:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916098, encodeId=2a111916098e8, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Dec 15 19:17:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662165, encodeId=117816621659e, content=<a href='/topic/show?id=27b4964139' target=_blank style='color:#2F92EE;'>#IL-17A单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9641, encryptionId=27b4964139, topicName=IL-17A单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b3425366251, createdName=ms7899726347904398, createdTime=Mon Aug 26 13:17:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931461, encodeId=c2b4193146153, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Feb 03 21:17:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652888, encodeId=a6011652888b6, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Dec 29 07:17:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674292, encodeId=21c016e42921d, content=<a href='/topic/show?id=a5261e119fc' target=_blank style='color:#2F92EE;'>#Taltz#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17119, encryptionId=a5261e119fc, topicName=Taltz)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9a26964526, createdName=hjwang88, createdTime=Sun Sep 08 21:17:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861312, encodeId=1f58186131243, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Oct 21 04:17:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265955, encodeId=d874126595582, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu Apr 25 11:17:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318698, encodeId=fb2c1318698de, content=<a href='/topic/show?id=6b4a845138d' target=_blank style='color:#2F92EE;'>#脊柱关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84513, encryptionId=6b4a845138d, topicName=脊柱关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2bcd469, createdName=fengting3, createdTime=Thu Apr 25 11:17:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374425, encodeId=014f13e4425b1, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9638, encryptionId=1727963861, topicName=IL-17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Thu Apr 25 11:17:00 CST 2019, time=2019-04-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2088740, encodeId=1d272088e40f9, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Nov 18 20:17:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916098, encodeId=2a111916098e8, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Dec 15 19:17:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662165, encodeId=117816621659e, content=<a href='/topic/show?id=27b4964139' target=_blank style='color:#2F92EE;'>#IL-17A单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9641, encryptionId=27b4964139, topicName=IL-17A单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b3425366251, createdName=ms7899726347904398, createdTime=Mon Aug 26 13:17:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931461, encodeId=c2b4193146153, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Feb 03 21:17:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652888, encodeId=a6011652888b6, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Dec 29 07:17:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674292, encodeId=21c016e42921d, content=<a href='/topic/show?id=a5261e119fc' target=_blank style='color:#2F92EE;'>#Taltz#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17119, encryptionId=a5261e119fc, topicName=Taltz)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9a26964526, createdName=hjwang88, createdTime=Sun Sep 08 21:17:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861312, encodeId=1f58186131243, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Oct 21 04:17:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265955, encodeId=d874126595582, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu Apr 25 11:17:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318698, encodeId=fb2c1318698de, content=<a href='/topic/show?id=6b4a845138d' target=_blank style='color:#2F92EE;'>#脊柱关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84513, encryptionId=6b4a845138d, topicName=脊柱关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2bcd469, createdName=fengting3, createdTime=Thu Apr 25 11:17:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374425, encodeId=014f13e4425b1, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9638, encryptionId=1727963861, topicName=IL-17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Thu Apr 25 11:17:00 CST 2019, time=2019-04-25, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2088740, encodeId=1d272088e40f9, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Nov 18 20:17:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916098, encodeId=2a111916098e8, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Dec 15 19:17:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662165, encodeId=117816621659e, content=<a href='/topic/show?id=27b4964139' target=_blank style='color:#2F92EE;'>#IL-17A单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9641, encryptionId=27b4964139, topicName=IL-17A单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b3425366251, createdName=ms7899726347904398, createdTime=Mon Aug 26 13:17:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931461, encodeId=c2b4193146153, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Feb 03 21:17:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652888, encodeId=a6011652888b6, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Dec 29 07:17:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674292, encodeId=21c016e42921d, content=<a href='/topic/show?id=a5261e119fc' target=_blank style='color:#2F92EE;'>#Taltz#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17119, encryptionId=a5261e119fc, topicName=Taltz)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9a26964526, createdName=hjwang88, createdTime=Sun Sep 08 21:17:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861312, encodeId=1f58186131243, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Oct 21 04:17:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265955, encodeId=d874126595582, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu Apr 25 11:17:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318698, encodeId=fb2c1318698de, content=<a href='/topic/show?id=6b4a845138d' target=_blank style='color:#2F92EE;'>#脊柱关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84513, encryptionId=6b4a845138d, topicName=脊柱关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2bcd469, createdName=fengting3, createdTime=Thu Apr 25 11:17:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374425, encodeId=014f13e4425b1, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9638, encryptionId=1727963861, topicName=IL-17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Thu Apr 25 11:17:00 CST 2019, time=2019-04-25, status=1, ipAttribution=)]
    2019-09-08 hjwang88
  7. [GetPortalCommentsPageByObjectIdResponse(id=2088740, encodeId=1d272088e40f9, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Nov 18 20:17:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916098, encodeId=2a111916098e8, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Dec 15 19:17:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662165, encodeId=117816621659e, content=<a href='/topic/show?id=27b4964139' target=_blank style='color:#2F92EE;'>#IL-17A单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9641, encryptionId=27b4964139, topicName=IL-17A单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b3425366251, createdName=ms7899726347904398, createdTime=Mon Aug 26 13:17:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931461, encodeId=c2b4193146153, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Feb 03 21:17:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652888, encodeId=a6011652888b6, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Dec 29 07:17:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674292, encodeId=21c016e42921d, content=<a href='/topic/show?id=a5261e119fc' target=_blank style='color:#2F92EE;'>#Taltz#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17119, encryptionId=a5261e119fc, topicName=Taltz)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9a26964526, createdName=hjwang88, createdTime=Sun Sep 08 21:17:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861312, encodeId=1f58186131243, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Oct 21 04:17:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265955, encodeId=d874126595582, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu Apr 25 11:17:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318698, encodeId=fb2c1318698de, content=<a href='/topic/show?id=6b4a845138d' target=_blank style='color:#2F92EE;'>#脊柱关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84513, encryptionId=6b4a845138d, topicName=脊柱关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2bcd469, createdName=fengting3, createdTime=Thu Apr 25 11:17:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374425, encodeId=014f13e4425b1, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9638, encryptionId=1727963861, topicName=IL-17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Thu Apr 25 11:17:00 CST 2019, time=2019-04-25, status=1, ipAttribution=)]
    2019-10-21 shizhenshan
  8. [GetPortalCommentsPageByObjectIdResponse(id=2088740, encodeId=1d272088e40f9, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Nov 18 20:17:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916098, encodeId=2a111916098e8, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Dec 15 19:17:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662165, encodeId=117816621659e, content=<a href='/topic/show?id=27b4964139' target=_blank style='color:#2F92EE;'>#IL-17A单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9641, encryptionId=27b4964139, topicName=IL-17A单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b3425366251, createdName=ms7899726347904398, createdTime=Mon Aug 26 13:17:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931461, encodeId=c2b4193146153, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Feb 03 21:17:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652888, encodeId=a6011652888b6, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Dec 29 07:17:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674292, encodeId=21c016e42921d, content=<a href='/topic/show?id=a5261e119fc' target=_blank style='color:#2F92EE;'>#Taltz#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17119, encryptionId=a5261e119fc, topicName=Taltz)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9a26964526, createdName=hjwang88, createdTime=Sun Sep 08 21:17:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861312, encodeId=1f58186131243, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Oct 21 04:17:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265955, encodeId=d874126595582, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu Apr 25 11:17:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318698, encodeId=fb2c1318698de, content=<a href='/topic/show?id=6b4a845138d' target=_blank style='color:#2F92EE;'>#脊柱关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84513, encryptionId=6b4a845138d, topicName=脊柱关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2bcd469, createdName=fengting3, createdTime=Thu Apr 25 11:17:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374425, encodeId=014f13e4425b1, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9638, encryptionId=1727963861, topicName=IL-17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Thu Apr 25 11:17:00 CST 2019, time=2019-04-25, status=1, ipAttribution=)]
    2019-04-25 lmm397
  9. [GetPortalCommentsPageByObjectIdResponse(id=2088740, encodeId=1d272088e40f9, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Nov 18 20:17:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916098, encodeId=2a111916098e8, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Dec 15 19:17:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662165, encodeId=117816621659e, content=<a href='/topic/show?id=27b4964139' target=_blank style='color:#2F92EE;'>#IL-17A单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9641, encryptionId=27b4964139, topicName=IL-17A单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b3425366251, createdName=ms7899726347904398, createdTime=Mon Aug 26 13:17:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931461, encodeId=c2b4193146153, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Feb 03 21:17:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652888, encodeId=a6011652888b6, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Dec 29 07:17:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674292, encodeId=21c016e42921d, content=<a href='/topic/show?id=a5261e119fc' target=_blank style='color:#2F92EE;'>#Taltz#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17119, encryptionId=a5261e119fc, topicName=Taltz)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9a26964526, createdName=hjwang88, createdTime=Sun Sep 08 21:17:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861312, encodeId=1f58186131243, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Oct 21 04:17:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265955, encodeId=d874126595582, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu Apr 25 11:17:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318698, encodeId=fb2c1318698de, content=<a href='/topic/show?id=6b4a845138d' target=_blank style='color:#2F92EE;'>#脊柱关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84513, encryptionId=6b4a845138d, topicName=脊柱关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2bcd469, createdName=fengting3, createdTime=Thu Apr 25 11:17:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374425, encodeId=014f13e4425b1, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9638, encryptionId=1727963861, topicName=IL-17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Thu Apr 25 11:17:00 CST 2019, time=2019-04-25, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=2088740, encodeId=1d272088e40f9, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Nov 18 20:17:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916098, encodeId=2a111916098e8, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Dec 15 19:17:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662165, encodeId=117816621659e, content=<a href='/topic/show?id=27b4964139' target=_blank style='color:#2F92EE;'>#IL-17A单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9641, encryptionId=27b4964139, topicName=IL-17A单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b3425366251, createdName=ms7899726347904398, createdTime=Mon Aug 26 13:17:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931461, encodeId=c2b4193146153, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Feb 03 21:17:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652888, encodeId=a6011652888b6, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Dec 29 07:17:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674292, encodeId=21c016e42921d, content=<a href='/topic/show?id=a5261e119fc' target=_blank style='color:#2F92EE;'>#Taltz#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17119, encryptionId=a5261e119fc, topicName=Taltz)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9a26964526, createdName=hjwang88, createdTime=Sun Sep 08 21:17:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861312, encodeId=1f58186131243, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Oct 21 04:17:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265955, encodeId=d874126595582, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu Apr 25 11:17:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318698, encodeId=fb2c1318698de, content=<a href='/topic/show?id=6b4a845138d' target=_blank style='color:#2F92EE;'>#脊柱关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84513, encryptionId=6b4a845138d, topicName=脊柱关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2bcd469, createdName=fengting3, createdTime=Thu Apr 25 11:17:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374425, encodeId=014f13e4425b1, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9638, encryptionId=1727963861, topicName=IL-17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Thu Apr 25 11:17:00 CST 2019, time=2019-04-25, status=1, ipAttribution=)]
    2019-04-25 fzwish20000

相关资讯

Lancet:IL-17A单抗ixekizumab可有效改善X线轴向骨关节炎患者症状

研究认为ixekizumab可有效改善X线轴向骨关节炎患者疾病症状